Reid M Huber bought $499K of Rapport Therapeutics (RAPP)
Executed Sep 12 2025, disclosed Sep 15 2025, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Sep 15 2025), the stock returned +10.2% (delay-adjusted); from the execution session (Sep 12 2025), +9.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Reid M Huber (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Rapport Therapeutics, Inc. (RAPP). Across 1 priced purchase filing, the average 21-session return was +9.3% from execution and +10.2% from disclosure (delay-adjusted; derived). The largest single filing was $499K of RAPP (20,400 sh × $24.48, as filed), executed Sep 12 2025.
Healthcare · Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transfo…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→